Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997752 | 1.00 | ADH1B (0.38) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL601670 | 0.79 | FDPS (0.45) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL601669 | 0.79 | FDPS (0.45) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL1468324 | 0.79 | FDPS (0.45) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL555055 | 0.78 | ALDH1A1 (0.40) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL158232 | 0.78 | ALDH1A1 (0.40) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL5862745 | 0.76 | ADH1B (0.38) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL8407475 | 0.76 | ADH1B (0.38) | ADH1BADH1CADH1ATSHRALDH1A1 | |
| SCHEMBL5857638 | 0.76 | ALDH1A1 (0.36) | ADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL9144390 | 0.76 | GRM2 (0.37) | ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | disclosed |
| WO-2021127547-A2 | MONOCLONAL ANTIBODY FUSIONS | QUIDEL CORPORATION (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3007704-B1 | COMBINATION THERAPY FOR ACROMEGALY | ANTISENSE THERAPEUTICS LTD (AU) | 2021-01-06 | — | — | EP | disclosed |
| EP-3424532-B1 | INFLUENZA VIRUS ANTIBODY COMPOSITIONS | SEC DEP FOR HEALTH AND SOCIAL CARE (GB) | 2021-01-06 | — | — | EP | disclosed |
| US-10744190-B2 | Method for suppressing spasmodic torticollis | IPSEN BIOINNOVATION LIMITED (GB) | 2020-08-18 | — | — | US | disclosed |
| US-10704038-B2 | Therapeutic fusion proteins | IPSEN BIOINNOVATION LIMTIED (GB) | 2020-07-07 | — | — | US | disclosed |
| US-10550377-B2 | Suppression of prostate cancer using a targeted clostridial neurotoxin | IPSEN BIOINNOVATION LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| EP-2719392-B1 | Fusion proteins for use in the treatment of acromegaly | IPSEN BIOINNOVATION LTD (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190127718-A1 | SUPPRESSION OF CANCER | IPSEN BIOINNOVATION LIMITED (GB) | 2019-05-02 | — | — | US | disclosed |
| EP-3473643-A1 | FUSION PROTEINS FOR USE IN THE TREATEMNT OF CANCER | Ipsen Bioinnovation Limited (GB) | 2019-04-24 | — | — | EP | disclosed |
| EP-0657174-A1 | Use of somatostatin | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0644893-A1 | INHIBITION OF TRAUMA-INDUCED TUMOR GROWTH | BIOMEASURE, INC. (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0536203-B1 | COMBINED TREATMENT WITH GnRH ANTAGONIST AND GnRH TO CONTROL GONADOTROPIN LEVELS IN MAMMALS | APPLIED RESEARCH SYSTEMS (AN) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994018231-A1 | INHIBITION OF TRAUMA-INDUCED TUMOR GROWTH | BIOMEASURE, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0422937-B1 | Fibrinogen receptor antagonists | MERCK & CO INC (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1991019743-A2 | COMBINED TREATMENT WITH GnRH ANTAGONIST AND GnRH TO CONTROL GONADOTROPIN LEVELS IN MAMMALS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1991-12-26 | — | — | WO | disclosed |
| EP-0422937-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0377665-A1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE. | UNIV TEXAS (US) | 1990-07-18 | — | — | EP | disclosed |
| WO-1989001944-A1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-03-09 | — | — | WO | disclosed |
| US-3986933-A | CANDIDA, MUTATION | INSTITUT FRANCAIS DU PETROL, DES CARBURANTS ET LUBRIFIANTS ET ENTREPRISE DE RECHERCHES ET D'ACTIVITIES PETROLIERES ELF (FR) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | GHSR, GHRHR, IGF1R | ADH1B 2823/4885ADH1C 3369/4885ADH1A 3790/4885 |
| US-10704038-B2 | Therapeutic fusion proteins | RPS27A, TMPRSS11D, TMPRSS15 | ADH1B 4663/4885ADH1C 4648/4885ADH1A 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.